This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
We did a comprehensive review of industry news in 2022Q1 (there was.. a lot of stuff to cover). This article…
Article
1 year ago ●
4 mins read
What is it? Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor (GCPR) and…
molecule
8 months ago ●
5 mins read
The FDA approved five new drugs in 2021 for use for genetic conditions, including molybdenum cofactor deficiency, Von Hippel-Lindau (VHL)…
Article
1 year ago ●
12 mins read
What is it? “Compound 25” is a selective, CNS-penetrant, ATP-competitive LRRK2 inhibitor that entered preclinical candidate enabling studies but was…
molecule
8 months ago ●
4 mins read
There were two novel small molecules approved in April 2022: mavacamten (Camzyos), an oral cardiac myosin inhibitor oteseconazole (Vivjoy), an…
Article
1 year ago ●
9 mins read
What is it? Compound 49 is an orally available CD73 inhibitor with dose-dependent PK/PD and an immune-mediated antitumor mechanism of…
molecule
8 months ago ●
3 mins read
Load More
